GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics, Children's Hospital Los Angeles, Division of Urology, Saban Research Institute, University of Southern California, Los Angeles, California.
Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy.
Stem Cells Transl Med. 2019 Jan;8(1):82-92. doi: 10.1002/sctm.18-0115. Epub 2018 Oct 9.
Significant progress has been made to advance stem cell products as potential therapies for kidney diseases: various kinds of stem cells can restore renal function in preclinical models of acute and chronic kidney injury. Nonetheless this literature contains contradictory results, and for this reason, we focus this review on reasons for apparent discrepancies in the literature, because they contribute to difficulty in translating renal regenerative therapies. Differences in methodologies used to derive and culture stem cells, even those from the same source, in addition to the lack of standardized renal disease animal models (both acute and chronic), are important considerations underlying contradictory results in the literature. We propose that harmonized rigorous protocols for characterization, handling, and delivery of stem cells in vivo could significantly advance the field, and present details of some suggested approaches to foster translation in the field of renal regeneration. Our goal is to encourage coordination of methodologies (standardization) and long-lasting collaborations to improve protocols and models to lead to reproducible, interpretable, high-quality preclinical data. This approach will certainly increase our chance to 1 day offer stem cell therapeutic options for patients with all-too-common renal diseases. Stem Cells Translational Medicine 2019;8:82-92.
各种类型的干细胞可以在急性和慢性肾损伤的临床前模型中恢复肾功能。尽管如此，这方面的文献中仍存在相互矛盾的结果，因此，我们将重点放在文献中明显差异的原因上，因为这些原因导致肾脏再生疗法的转化困难。用于衍生和培养干细胞的方法存在差异，即使是来自同一来源的干细胞也是如此，此外，缺乏标准化的急性和慢性肾脏病动物模型，这是导致文献中出现相互矛盾结果的重要原因。我们提出，对干细胞在体内的特性、处理和传递进行协调一致的严格方案，可以极大地推动该领域的发展，并提出了一些促进肾脏再生领域转化的建议方法的细节。我们的目标是鼓励方法学的协调（标准化）和长期合作，以改进方案和模型，从而产生可重复、可解释、高质量的临床前数据。这种方法肯定会增加我们为患有常见肾脏疾病的患者提供干细胞治疗选择的机会。《干细胞转化医学》2019；8:82-92。
